RE: Diverse product range coming to limelight: article regarding HEP-C published yesterday!5 Mar 2023 09:35
Overall, Genedrive® performed well as a point-of-service assay to seamlessly and more rapidly link participants to care. We have demonstrated that in this challenging patient population, traditional models of facility-based care will not achieve the scale-up and treatment impact required to eliminate hepatitis C in this population